+

WO2008140624A3 - Methods and compositions related to hybird nanoparticles - Google Patents

Methods and compositions related to hybird nanoparticles Download PDF

Info

Publication number
WO2008140624A3
WO2008140624A3 PCT/US2007/088846 US2007088846W WO2008140624A3 WO 2008140624 A3 WO2008140624 A3 WO 2008140624A3 US 2007088846 W US2007088846 W US 2007088846W WO 2008140624 A3 WO2008140624 A3 WO 2008140624A3
Authority
WO
WIPO (PCT)
Prior art keywords
hybird
nanoparticles
methods
compositions related
nanoparticle
Prior art date
Application number
PCT/US2007/088846
Other languages
French (fr)
Other versions
WO2008140624A2 (en
Inventor
Konstantin Sokolov
Thomas Milner
Timothy Larson
James Bankson
Jesse Aaron
Jungwan Oh
Xiaojun Ji
Chun Li
Original Assignee
The Board Of Regents Of The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Regents Of The University Of Texas System filed Critical The Board Of Regents Of The University Of Texas System
Publication of WO2008140624A2 publication Critical patent/WO2008140624A2/en
Publication of WO2008140624A3 publication Critical patent/WO2008140624A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/183—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Embodiments of the invention include a hybrid nanoparticle comprising an optically interrogatable component and a magnetically interrogatable component. Particularly, a hybrid nanoparticle coupled with a targeting moiety that selectively associates the nanoparticle with a particular biological location, cell, tissue, or organ.
PCT/US2007/088846 2006-12-22 2007-12-26 Methods and compositions related to hybird nanoparticles WO2008140624A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87156906P 2006-12-22 2006-12-22
US60/871,569 2006-12-22

Publications (2)

Publication Number Publication Date
WO2008140624A2 WO2008140624A2 (en) 2008-11-20
WO2008140624A3 true WO2008140624A3 (en) 2010-04-22

Family

ID=39870411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/088846 WO2008140624A2 (en) 2006-12-22 2007-12-26 Methods and compositions related to hybird nanoparticles

Country Status (1)

Country Link
WO (1) WO2008140624A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8335570B2 (en) 2008-10-09 2012-12-18 Boston Scientific Neuromodulation Corporation Electrical stimulation leads having RF compatibility and methods of use and manufacture
IT1394302B1 (en) * 2009-05-20 2012-06-06 Uni Degli Studi Perugia "NEW HYBRID PARTICLES AND THEIR USE IN DIAGNOSIS AND THERAPY"
ES2359411B1 (en) * 2009-10-19 2012-04-03 Universidad De Zaragoza METHOD OF AUTHENTICATION OF OBJECTS.
CN101966344B (en) * 2010-10-29 2012-04-11 中国科学院上海硅酸盐研究所 Hollow core-shell nanometer mesoporous medicament carrying system with magnetism and luminescent performance, preparation method and application thereof
KR101304427B1 (en) * 2011-04-12 2013-09-05 한국과학기술연구원 Recyclable porous bead - satellite nanoparticles composite and the fabrication method thereof
US9417240B2 (en) 2011-05-27 2016-08-16 Drexel University Capped and conjugated quantum dots
CN102364616B (en) * 2011-09-22 2015-08-19 华南师范大学 The nano composite material Fe of nucleocapsid structure 3o 4@PS@Ag and preparation method thereof
WO2013170229A1 (en) * 2012-05-11 2013-11-14 Vanderbilt University Detecting antigens such as bacterial quorum sensing proteins
DE102012017044A1 (en) * 2012-08-29 2014-03-06 Nano4Imaging Gmbh Multi-contrast agent useful in fillers for bone and teeth, comprises particles made of sheath comprising contrast agent for computed tomography and core comprising contrast agent for magnetic resonance imaging
US9730635B2 (en) 2013-06-21 2017-08-15 Verily Life Sciences Llc Physiological measurement using wearable device
WO2015034918A1 (en) 2013-09-05 2015-03-12 The Regents Of The University Of Michigan Core-satellite nanocomposites for mri and photothermal therapy
US9504405B2 (en) 2013-10-23 2016-11-29 Verily Life Sciences Llc Spatial modulation of magnetic particles in vasculature by external magnetic field
US10542918B2 (en) 2013-10-23 2020-01-28 Verily Life Sciences Llc Modulation of a response signal to distinguish between analyte and background signals
JP6387409B2 (en) * 2013-10-23 2018-09-05 ヴェリリー ライフ サイエンシズ エルエルシー Spatial modulation of magnetic particles in vascular system by external magnetic field
US10039491B2 (en) 2014-06-30 2018-08-07 Verily Life Sciences Llc Methods for reducing noise in optical biological sensors
US9874554B1 (en) 2014-07-16 2018-01-23 Verily Life Sciences Llc Aptamer-based in vivo diagnostic system
US9910035B1 (en) 2014-07-16 2018-03-06 Verily Life Sciences Llc Polyvalent functionalized nanoparticle-based in vivo diagnostic system
LU100581B1 (en) * 2017-12-20 2019-06-28 Luxembourg Inst Science & Tech List Method for manufacturing mesoporous silica nanoparticles with encapsulated superparamagnetic clusters
CN108904800B (en) * 2018-07-07 2021-03-26 上海大学 Upconversion nano-hybrid system based on heterogeneous growth of nano-palladium, preparation method and application
US11890299B2 (en) 2019-06-27 2024-02-06 Hologic, Inc. Ablation agent and methods of use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JEONG ET AL: "Enhanced reusability of hexa-arginine-tagged esterase immobilized on gold-coated magnetic nanoparticles", ANALYTICA CHIMICA ACTA, ELSEVIER, AMSTERDAM, NL, vol. 569, no. 1-2, 31 May 2006 (2006-05-31), pages 203 - 209, XP025048205, ISSN: 0003-2670 *
KOO Y E L ET AL: "Brain cancer diagnosis and therapy with nanoplatforms", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 58, no. 14, 1 December 2006 (2006-12-01), pages 1556 - 1577, XP024892094, ISSN: 0169-409X, [retrieved on 20061201] *
LARSON T A ET AL: "Hybrid plasmonic magnetic nanoparticles as molecular specific agents for MRI/optical imaging and photothermal therapy of cancer cells", NANOTECHNOLOGY 20070815 GB, vol. 18, no. 32, 15 August 2007 (2007-08-15), XP002571018 *
LIM ET AL: "Design and synthesis of plasmonic magnetic nanoparticles", JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 311, no. 1, 20 December 2006 (2006-12-20), pages 78 - 83, XP022036635, ISSN: 0304-8853 *
LYON J L ET AL: "Synthesis of Fe oxide core/Au shell nanoparticles by iterative hydroxylamine seeding", NANO LETTERS AMERICAN CHEM. SOC USA, vol. 4, no. 4, April 2004 (2004-04-01), pages 719 - 723, XP002571015, ISSN: 1530-6984 *
SOSNOVIK DAVID E ET AL: "Fluorescence tomography and magnetic resonance imaging of myocardial macrophage infiltration in infarcted myocardium in vivo", CIRCULATION, vol. 115, no. 11, March 2007 (2007-03-01), pages 1384 - 1391, XP002571026, ISSN: 0009-7322 *

Also Published As

Publication number Publication date
WO2008140624A2 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
WO2008140624A3 (en) Methods and compositions related to hybird nanoparticles
WO2006133271A3 (en) Compositions and methods relating to target-specific photodynamic therapy
WO2009067245A3 (en) Compositions and methods for tissue repair
EP3320911A3 (en) Activin-actrii antagonists and uses for increasing red blood cell levels
WO2010059253A3 (en) Methods and compositions for localized agent delivery
AU306408S (en) Tractor
WO2007089864A3 (en) Sutures and fibrosing agents
WO2008128051A3 (en) Fluorescent nanoparticle compositions, methods and devices
WO2008073856A3 (en) Delivery of nanoparticles and/or agents to cells
WO2009100137A3 (en) Magnetic cells for localizing delivery and tissue repair
WO2007053731A3 (en) Expression of soluble factor viii proteins in bacteria
EP2733209A3 (en) Variant Buttiauxella sp.phytases having altered properties
WO2008036495A3 (en) Medical balloons with modified surfaces
EP1992270A4 (en) LIVING BODY OBSERVATION EQUIPMENT
WO2009129649A8 (en) Biocompatible polymer and magnetic nanoparticle with biocompatibility
FR2907870B1 (en) HYDRAULIC DIFFERENTIAL IMPROVED IN PARTICULAR FOR INTEGRATED DRIVE GENERATOR.
WO2009112488A3 (en) Polyether polyol dendron conjugates with effector molecules for biological targeting
EP1803596A3 (en) Press-molded door beam of vehicle, having longitudinal groove part protruding from beam end
EP1942603A3 (en) Embedded mechanism for platform vulnerability assessment
WO2008048952A3 (en) Multi-lumen catheter and endoscopic method
TW200724904A (en) Magnetic nanoparticles with fluorescent and specific targeting functions
WO2008033804A3 (en) Quantum dot barcode structures and uses thereof
WO2005113747A3 (en) Multicellular tissue and organ culture systems
AU315068S (en) Actuator
EP2468772A3 (en) Antibodies to EGFL7 and methods for their use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07874392

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07874392

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载